BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 24433105)

  • 1. An overview of the progress in the treatment of multiple myeloma.
    Kyle RA; Rajkumar SV
    Expert Rev Hematol; 2014 Feb; 7(1):5-7. PubMed ID: 24433105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging therapies in multiple myeloma.
    El-Amm J; Tabbara IA
    Am J Clin Oncol; 2015 Jun; 38(3):315-21. PubMed ID: 23934133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thalidomide and lenalidomide in multiple myeloma.
    Mazumder A; Jagannath S
    Best Pract Res Clin Haematol; 2006; 19(4):769-80. PubMed ID: 16997182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Multiple myeloma and other plasma cell dyscrasias].
    Nagy Z
    Magy Onkol; 2016 Jun; 60(2):154-63. PubMed ID: 27275642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple myeloma: treatment evolution.
    San Miguel JF; Mateos MV; Ocio E; Garcia-Sanz R
    Hematology; 2012 Apr; 17 Suppl 1():S3-6. PubMed ID: 22507766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The emerging role of consolidation and maintenance therapy for transplant-eligible multiple myeloma patients.
    McCarthy PL; Einsele H; Attal M; Giralt S
    Expert Rev Hematol; 2014 Feb; 7(1):55-66. PubMed ID: 24471885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel generation of agents with proven clinical activity in multiple myeloma.
    Mateos MV; Ocio EM; San Miguel JF
    Semin Oncol; 2013 Oct; 40(5):618-33. PubMed ID: 24135407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple myeloma: is a shift toward continuous therapy needed to move forward?
    Guglielmelli T; Palumbo A
    Expert Rev Hematol; 2015 Jun; 8(3):253-6. PubMed ID: 25582032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice.
    Lee HS; Min CK
    Korean J Intern Med; 2016 Sep; 31(5):809-19. PubMed ID: 27604793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma.
    Highsmith KN; Chen SE; Horowitz S
    Pharmacotherapy; 2014 Sep; 34(9):927-40. PubMed ID: 25044413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance therapy for multiple myeloma.
    McCarthy PL; Palumbo A
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):839-59. PubMed ID: 25212886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple myeloma maintenance therapy: a review of the pharmacologic treatment.
    Shank BR; Brown VT; Schwartz RN
    J Oncol Pharm Pract; 2015 Feb; 21(1):36-51. PubMed ID: 24395544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
    Palumbo A; Attal M; Roussel M
    Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of carfilzomib in the treatment of multiple myeloma.
    Khan RZ; Badros A
    Expert Rev Hematol; 2012 Aug; 5(4):361-72. PubMed ID: 22992230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies.
    Morgan G
    Blood Rev; 2010 Nov; 24 Suppl 1():S27-32. PubMed ID: 21126634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunomodulatory Drugs (IMiDs) in Multiple Myeloma.
    Raza S; Safyan RA; Lentzsch S
    Curr Cancer Drug Targets; 2017; 17(9):846-857. PubMed ID: 28201976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New treatment strategy of multiple myeloma for cure].
    Murakami H; Handa H
    Gan To Kagaku Ryoho; 2006 Apr; 33(4):417-23. PubMed ID: 16612147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current strategies for treatment of relapsed/refractory multiple myeloma.
    Laubach JP; Voorhees PM; Hassoun H; Jakubowiak A; Lonial S; Richardson PG
    Expert Rev Hematol; 2014 Feb; 7(1):97-111. PubMed ID: 24471924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenalidomide in multiple myeloma.
    Richardson PG; Mitsiades C; Hideshima T; Anderson KC
    Expert Rev Anticancer Ther; 2006 Aug; 6(8):1165-73. PubMed ID: 16925483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma.
    Salvini M; Bonello F; Boccadoro M; Larocca A
    Expert Rev Anticancer Ther; 2017 Jan; 17(1):75-87. PubMed ID: 27894203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.